Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

Hyperbaric oxygen therapy improves outcomes of umbilical cord blood transplant patients

For the past 27 years, cord blood transplants have been a life-saving treatment option for thousands of people with leukemia, non-Hodgkins lymphoma, Hodgkins disease and myelodysplastic disorders. Cord blood helps replace cancerous blood cells and replenish a patient's own bone marrow and immune system. Even with its success, researchers are continually looking for ways to improve the transplant process and increase cure rates.

24 Sep 2015

Scientists trace out intricate molecular pathway that may explain tamoxifen resistance in breast cancer patients

For reasons unknown, many patients with breast cancer treated with the estrogen receptor-blocking drug tamoxifen eventually become resistant to the treatment despite the fact that their cancer cells still have the estrogen receptor proteins that the drug normally targets.

24 Sep 2015

Study raises questions about direct applicability of clinical trial data for cancer drugs

When prescribing newly approved drugs, physicians rely on data from clinical trials to understand the benefits and risks of those drugs for patients. But a study published in the Journal of Oncology Practice showed that for certain cancer drugs, participants in clinical trials are often not representative of the patients that ultimately take the drugs, raising questions about the direct applicability of trial data.

24 Sep 2015

Innovative new device improves breast cancer treatment

A surgeon with the Breast Health Center at Women & Infants Hospital of Rhode Island, a Care New England hospital, is among the first in New England to adopt an innovative new device that improves the treatment of breast cancer by more precisely targeting radiation treatment and providing for better follow-up exams.

23 Sep 2015

OncoGenex reports results from Phase 2 Rainier study in patients with untreated metastatic pancreatic cancer

OncoGenex Pharmaceuticals, Inc. announced today initial results from the Phase 2 Rainier study evaluating apatorsen in combination with ABRAXANE (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) and gemcitabine compared to ABRAXANE and gemcitabine alone in patients with untreated metastatic pancreatic cancer.

23 Sep 2015

UT Southwestern surgeons help pioneer minimally invasive ear surgery

UT Southwestern Medical Center surgeons are helping to pioneer a trend that extends the advantages and benefits of minimally invasive surgery to patients who need middle ear surgery.

23 Sep 2015

People in addiction treatment programs more likely to use tobacco

People in addiction treatment programs around the world use tobacco at two to three times the rate of people who are not being treated for addiction, according to a review of research studies from 20 countries other than the United States.

23 Sep 2015

Johns Hopkins scientists discover earliest premalignant genetic changes that mark potential onset of lung cancer

Working with tissue, blood and DNA from six people with precancerous and cancerous lung lesions, a team of Johns Hopkins scientists has identified what it believes are among the very earliest “premalignant” genetic changes that mark the potential onset of the most common and deadliest form of disease.

23 Sep 2015

Drug combination delivers effective punch against one form of pancreatic cancer

One form of pancreatic cancer has a new enemy: a two-drug combination discovered by UF Health researchers that inhibits tumors and kills cancer cells in mouse models.

22 Sep 2015

FDA approves LONSURF for treatment of patients with metastatic colorectal cancer

Taiho Oncology, Inc. (U.S.), a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), today announced that the U.S. Food and Drug Administration approved LONSURF (trifluridine and tipiracil), formerly known as TAS-102, for the treatment of patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy.

22 Sep 2015

BWH, DFCI researchers receive $10 million to test effectiveness of aspirin in women with breast cancer

Researchers from Brigham and Women's Hospital and Dana-Farber Cancer Institute have received a $10 million Breakthrough Award from the Department of Defense's Office of the Congressionally Directed Medical Research Program to test whether aspirin helps women with breast cancer avoid recurrence and live longer.

22 Sep 2015

Arsenic trioxide feasible in low-, high-risk acute promyelocytic leukaemia

The use of arsenic trioxide instead of idarubicin in combination with all-trans retinoic acid is a feasible option in patients with acute promyelocytic leukaemia, regardless of risk level, suggests a phase III trial.

21 Sep 2015

Invitae launches new education program to increase awareness of genetic testing for hereditary cancer

A new survey released today shows 73 percent of Americans are aware of genetic testing for hereditary cancers – a significant increase over just a few years ago. Previous research found that in 2010 less than half of the Americans surveyed said they were aware of genetic testing. Dubbed the "Angelina Jolie Effect," the current data highlight the far-reaching impact of Angelina Jolie's public discussion of genetic testing for hereditary cancer.

21 Sep 2015

Boehringer Ingelheim, BioMed X apply crowdsourcing approach to establish research team for identifying COPD treatment

Boehringer Ingelheim and BioMed X announced today that they have successfully applied a crowdsourcing approach to establish a research team of outstanding scientists from around the world with bright ideas, who will endeavor to identify new approaches for the treatment of patients with chronic obstructive pulmonary disease (COPD).

21 Sep 2015

Ups and downs of incorporating new treatment to reduce oxaliplatin-induced neuropathy

In this age of the 24-hour news cycle, instant access to all information everywhere, PubMed, LinkedIn, Facebook, Twitter and hundreds of other ways to glean and share knowledge beyond the traditional stack of printed journals delivered to their door, physicians continue to struggle to arm themselves with the most effective therapies.

21 Sep 2015

BGB324 shows enhanced tumour clearance in mouse carcinoma models

BerGenBio AS, an oncology biopharmaceutical company, has announced new preclinical data on lead compound, BGB324, in combination with immune checkpoint inhibitors, has been presented as a poster at CRI-CIMT-EATI-AACR - The Inaugural International Cancer Immunotherapy Conference: Translating Science into Survival, in New York.

21 Sep 2015

Artificial intelligence may improve outcomes in breast cancer patients

Western University researchers are working on a way to use artificial intelligence to predict a patient's response to two common chemotherapy medications used to treat breast cancer - paclitaxel and gemcitabine.

19 Sep 2015

Genetically engineered vaccine eradicates precancerous cervical lesions

Scientists have used a genetically engineered vaccine to successfully eradicate high-grade precancerous cervical lesions in nearly one-half of women who received the vaccine in a clinical trial. The goal, say the scientists, was to find nonsurgical ways to treat precancerous lesions caused by HPV.

18 Sep 2015

Thomas Jefferson University provides routine genomic fingerprinting to cancer patients

Cancer medicine is moving towards understanding what drives each particular patient's cancer. But not every patient has had access to this level of individualized care.

18 Sep 2015

PharmaMar begins phase II 'Basket' trial to evaluate safety, efficacy of PM1183 in advanced solid tumors

PharmaMar announced today the start of a multicenter, international, open-label, exploratory phase II "Basket" trial (NCT02454972) to evaluate the efficacy and safety of the anticancer agent PM1183 (lurbinectedin) in advanced solid tumors.

18 Sep 2015

Oncology News and Research

Further Reading

Hyperbaric oxygen therapy improves outcomes of umbilical cord blood transplant patients

Scientists trace out intricate molecular pathway that may explain tamoxifen resistance in breast cancer patients

Study raises questions about direct applicability of clinical trial data for cancer drugs

Innovative new device improves breast cancer treatment

OncoGenex reports results from Phase 2 Rainier study in patients with untreated metastatic pancreatic cancer

UT Southwestern surgeons help pioneer minimally invasive ear surgery

People in addiction treatment programs more likely to use tobacco

Johns Hopkins scientists discover earliest premalignant genetic changes that mark potential onset of lung cancer

Drug combination delivers effective punch against one form of pancreatic cancer

FDA approves LONSURF for treatment of patients with metastatic colorectal cancer

BWH, DFCI researchers receive $10 million to test effectiveness of aspirin in women with breast cancer

Arsenic trioxide feasible in low-, high-risk acute promyelocytic leukaemia

Invitae launches new education program to increase awareness of genetic testing for hereditary cancer

Boehringer Ingelheim, BioMed X apply crowdsourcing approach to establish research team for identifying COPD treatment

Ups and downs of incorporating new treatment to reduce oxaliplatin-induced neuropathy

BGB324 shows enhanced tumour clearance in mouse carcinoma models

Artificial intelligence may improve outcomes in breast cancer patients

Genetically engineered vaccine eradicates precancerous cervical lesions

Thomas Jefferson University provides routine genomic fingerprinting to cancer patients

PharmaMar begins phase II 'Basket' trial to evaluate safety, efficacy of PM1183 in advanced solid tumors

Your guide to microplate readers for cancer research eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News